Abstract
Description
The Pharmacogenomic Partnering Terms and Agreements report provides
comprehensive understanding and unprecedented access to the pharmacogenomic
partnering deals and agreements entered into by the worlds leading healthcare
companies.
The report provides a detailed understanding and analysis of how and why
companies enter pharmacogenomic partnering deals. The majority of deals are
discovery or development stage whereby the licensee obtains a right or an
option right to license the licensors pharmacogenomic technology. These deals
tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This report contains over 500 links to online copies of actual pharmacogenomic
deals and contract documents as submitted to the Securities Exchange
Commission by companies and their partners. Contract documents provide the
answers to numerous questions about a prospective partner's flexibility on a
wide range of important issues, many of which will have a significant impact
on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of pharmacogenomic
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an overview of the trends in pharmacogenomic
dealmaking since 2005, including details of average headline, upfront,
milestone and royalty terms.
Chapter 3 provides a review of the leading pharmacogenomic deals since 2007.
Deals are listed by headline value, signed by bigpharma, most active
bigpharma, and most active of all biopharma companies. Where the deal has an
agreement contract published at the SEC a link provides online access to the
contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of pharmacogenomic
deals as well as contract documents available in the public domain. Where
available, each deal title links via Weblink to an online version of the
actual contract document, providing easy access to each contract document on
demand.
Chapter 5 provides a comprehensive and detailed review of pharmacogenomic
partnering deals signed and announced since 2007, where a contract document is
available in the public domain. The chapter is organized by company A-Z, stage
of development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), and specific therapy focus. Each deal title links via Weblink
to an online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in pharmacogenomic partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
pharmacogenomic technologies and products.
Pharmacogenomic Partnering Terms and Agreements is intended to provide the
reader with an in-depth understanding and access to pharmacogenomic trends and
structure of deals entered into by leading companies worldwide.
Pharmacogenomic Partnering Terms and Agreements includes:
- Trends in pharmacogenomic dealmaking in the biopharma industry since 2007
- Analysis of pharmacogenomic deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life pharmacogenomic deals
- Access to over 500 pharmacogenomic contract documents
- The leading pharmacogenomic deals by value since 2007
- Most active pharmacogenomic dealmakers since 2007
- The leading pharmacogenomic partnering resources
In Pharmacogenomic Partnering Terms and Agreements, the available contracts
are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
Report scope
The Pharmacogenomic Partnering Terms and Agreements report provides
comprehensive access to available deals and contract documents for over 500
pharmacogenomic deals. Analyzing actual contract agreements allows assessment
of the following:
- What are the precise pharmacogenomic rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Pharmacogenomic Partnering Terms and Agreements provides the reader with the
following key benefits:
- In-depth understanding of pharmacogenomic deal trends since 2007
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of pharmacogenomic agreements with numerous real
life case studies
- Access to over 120 pharmacogenomic online deals entered into by the
world's biopharma companies
- Detailed access to actual pharmacogenomic contracts enter into by the
leading fifty bigpharma companies
- Insight into the terms included in a pharmacogenomic agreement, together
with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in pharmacogenomic dealmaking
- 2.1. Introduction
- 2.2. Pharmacogenomic partnering over the years
- 2.3. Bigpharma pharmacogenomic dealmaking activity
- 2.4. Most active pharmacogenomics dealmakers
- 2.5. Pharmacogenomic partnering by deal type
- 2.6. Pharmacogenomic partnering by disease type
- 2.7 Average deal terms for pharmacogenomics
- 2.7.1 Pharmacogenomic headline values
- 2.7.2 Pharmacogenomic upfront payments
- 2.7.3 Pharmacogenomic milestone payments
- 2.7.4 Pharmacogenomic royalty rates
Chapter 3 - Leading pharmacogenomic deals
- 3.1. Introduction
- 3.2. Top pharmacogenomic deals by value
- 3.3. Top pharmacogenomic deals involving bigpharma
Chapter 4 - Bigpharma pharmacogenomic deals
- 4.1. Introduction
- 4.2. How to use bigpharma pharmacogenomic partnering deals
- 4.3. Bigpharma pharmacogenomic partnering company profiles
- Abbott
- AstraZeneca
- Bayer
- Bristol-Myers Squibb
- Eisai
- Eli Lilly
- Gilead Sciences
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co
- Novartis
- Takeda
Chapter 5 - Pharmacogenomic dealmaking directory
- 5.1. Introduction
- 5.2. Company A-Z
- 454 Life Sciences
- Abbott Laboratories
- Abbott Molecular
- Abyntek Biopharma
- AEterna Zentaris
- Affomix
- Akonni Biosystems
- Alere GmbH
- Algeta
- Althea Technologies
- Ambry Genetics
- American Society of Clinical Oncology (ASCO)
- Antitope
- Applied BioCode
- Applied Biosystems
- Aptiv Solutions
- Ariana Pharma
- Array Biopharma
- AssureRx Health
- AstraZeneca
- Astrimmune
- Asuragen
- AutoGenomics
- AVEO Pharmaceuticals
- Aviir Diagnostics
- Bayer
- Bayer Vital
- Beckman Coulter
- Beijing Health Bureau
- Biomatrica
- BioMerieux
- BioReference Laboratories
- BiPar Sciences
- Boulder Diagnostics
- Bristol-Myers Squibb
- Cabernet Pharmaceuticals
- Caliper Life Sciences
- Cancer Genetics
- CancerGuide Diagnostics
- Caris Life Sciences
- Case Western Reserve University
- Catholic Health Initiatives
- Celera
- Celera Diagnostics
- Cephalon
- Cernostics
- Champions Oncology
- ChanTest
- CHDI Foundation
- Clarient
- Clinical Data
- CollabRx
- CombiMatrix
- Complete Genomics
- CPGR
- Critical Path Institute (C-Path)
- Curidium Medica
- Cylene Pharma
- Dako
- Dana-Farber Cancer Institute
- DeCODE Genetics
- Definiens
- Deutsches Herzzentrum
- DiagnoCure
- Diagnostic Hybrids
- DNA Genotek
- Duke University
- DxS
- Eisai
- Eli Lilly
- Empire Genomics
- EraGen Biosciences
- Erytech
- Essential Molecular Testing
- Exact Sciences
- Falco
- Florida Hospital
- Food and Drug Administration (FDA)
- Foundation Medicine
- Fox Chase Cancer Center
- GE Healthcare
- Genetic Technologies
- Genome Diagnostics
- Genome Quebec
- Gentris
- German Cancer Research Center
- Gilead Sciences
- GlaxoSmithKline
- Golden Helix
- Government of Germany
- H3 Biomedicine
- Harvard-Partners Center for Genetics and Genomics
- Health Discovery
- HealthCore
- Helmholtz Institute in Saarbrucken
- HistoRx
- Horizon Discovery
- Hospices Civils de Lyon
- Hospital Clinic of Barcelona
- Hospital for Special Surgery
- Icon
- Illumina
- ImaginAb
- InforSense
- Inova Health System
- Institut Pasteur
- Invitrogen
- Ipsen
- JDRF
- Johns Hopkins University
- Johnson & Johnson
- Key Genomics
- KeyMarker
- KINAXO Biotechnologies
- KSB Diagnostics
- Lab21
- LabCorp
- Leica Microsystems
- Lipomics Technologies
- London Genetics
- Luminex
- Lumiphore
- Massachusetts General Hospital
- MD Anderson Cancer Center
- MDxHealth
- Medco Health Solutions
- Medco Research Institute
- Medical University South Carolina
- Medinnova
- Memorial Sloan Kettering Cancer Center
- Merck & Co
- Metabolon
- Metamark Genetics
- Minerva Biotechnologies
- Molecular Devices
- MolecularMD
- Montreal Heart Institute
- Morphisto
- MP Biomedicals
- Multimmune
- MultiPlan
- Myriad Genetics
- Nanosphere
- National Research Council Canada
- National Science Foundation
- Neogenomics
- New York University
- Novartis
- On-Q-ity
- Oncodesign
- OncoMethylome
- OPKO Health
- OvaGene Oncology
- Perlegen Sciences
- Pfizer
- PGxHealth
- PGXL
- PGXL Partners
- Pikamab
- Population Genetics Technologies
- Predictive Biomarker Sciences
- Prometheus
- Pronto Diagnostics
- PROOF Centre of Excellence for Commercialization and Research
- Qiagen
- Qualcomm
- Quest Diagnostics
- Quintiles
- Read-Gene
- Research Institute of the Hospital Universitari Vall d'Hebron
- Response Genetics
- Roche Diagnostics
- Rules-Based Medicine
- Russian Nanotechnology Corporation
- Sage Bionetworks
- SAIC-Frederick
- Saladax Biomedical
- Sanford Burnham Institute
- SC Liver Research Consortium (SCLRC)
- Scripps Health
- Scripps Translational Science Institute
- Seegene
- Selvita
- Shanghai Centers for Disease Control and Prevention
- Shanghai Institutes of Preventative Medicine
- Signal Genetics
- SimuGen
- Sinovac Biotech
- Sirius Genomics
- Sirius Laboratories
- Smart Personalized Medicine
- Source Bioscience
- Source MDx
- Spacelabs Healthcare
- Spartan Bioscience
- Stone Ridge Technology
- SuperNova Diagnostics
- SureGene
- Takeda Pharmaceutical
- Tarrot
- TcLand Expression
- TGen Drug Development
- The Biomarker Factory
- Transgene
- Transgenomic
- UAB Research Foundation
- Unibioscreen
- United Kingdom Critical Care Genomics
- University Gottingen
- University of Bergen
- University of California San Francisco (UCSF)
- University of Montreal Pharmacogenomics Centre
- University of North Carolina
- University of Pittsburgh
- University of Wurzburg
- US Preventive Medicine
- Vanda Pharmaceuticals
- Vermillion
- XDx
- Yale University
- Zinfandel Pharmaceuticals
- 5.3. By stage of development
- Discovery
- Marketed
- Phase I
- Phase II
- Preclinical
- 5.4. By deal type
- Asset purchase
- Co-development
- Collaborative R&D
- Contract service
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Research
- Supply
- 5.5. By therapy area
- Partnering deals directory (Jan 2007 to Feb 2013) - By therapy area
- Cardiovascular
- Central nervous system
- Dermatology
- Gastrointestinal
- Genetic disorders
- Hematology
- Hospital care
- Immunology
- Infectives
- Metabolic
- Musculoskeletal
- Oncology
- Pediatrics
- Psychiatry
- Public health
- Respiratory
Chapter 6 -Pharmacogenomic dealmaking by technology type
- 6.1. Introduction
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Bioprocessing
- Blood products
- Cell culture
- Clinical testing
- Devices
- Diagnostics
- Discovery tools
- Drug delivery
- Enabling technology
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Nanotechnology
- Peptides
- Personalised medicine
- Pharmacogenomics
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Software tools
- Stem cells
- Toxicity
- Vaccines
Chapter 7 - Pharmacogenomic partnering resource center
- 7.1. Online pharmacogenomic partnering
- 7.2. Pharmacogenomic partnering events
- 7.3. Further reading on pharmacogenomic dealmaking
Appendices
- Appendix 1 - Deal type definitions
- Appendix 2 - Example pharmacogenomic partnering agreement
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
- Order Form - Therapy Reports
Table of figures
- Figure 1: Pharmacogenomic partnering since 2007
- Figure 2: Bigpharma - top 50 - pharmacogenomic deals 2007 to 2013
- Figure 3: Bigpharma pharmacogenomics deal frequency - 2007 to 2013
- Figure 4: Active pharmacogenomics dealmaking activity- 2007 to 2013
- Figure 5: Pharmacogenomic partnering by deal type since 2007
- Figure 6: Pharmacogenomic partnering by disease type since 2007
- Figure 7: Pharmacogenomic partnering by oncology target since 2007
- Figure 8: Pharmacogenomic deals with a headline value
- Figure 9: Pharmacogenomic deal headline value distribution, US$million -
Discovery
- Figure 10: Pharmacogenomic deal headline value distribution, US$million -
Preclinical
- Figure 11: Pharmacogenomic deal headline value distribution, US$million -
Marketed
- Figure 12: Pharmacogenomic deals with upfront payment values
- Figure 13: Pharmacogenomic deal upfront payment distribution, US$million-
Preclinical
- Figure 14: Pharmacogenomic deals with milestone payments
- Figure 15: Top pharmacogenomic deals by value since 2007
- Figure 16: Top pharmacogenomic deals signed by bigpharma value since 2007
- Figure 17: Recent deals (Jan 2007 to Feb 2013) - By therapy area
(Cardiovascular)
- Figure 18: Recent deals (Jan 2007 to Feb 2013) - By therapy area (CNS)
- Figure 19: Recent deals (Jan 2007 to Feb 2013) - By therapy area
(Gastrointestinal)
- Figure 20: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Genetic
disorders)
- Figure 21: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Hospital
care)
- Figure 22: Recent deals (Jan 2007 to Feb 2013) - By therapy area
(Immunology)
- Figure 23: Recent deals (Jan 2007 to Feb 2013) - By therapy area
(Infectives)
- Figure 24: Recent deals (Jan 2007 to Feb 2013) - By therapy area
(Metabolic)
- Figure 25: Recent deals (Jan 2007 to Feb 2013) - By therapy area
(Musculoskeletal)
- Figure 26: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Oncology)
- Figure 27: Recent deals (Jan 2007 to Feb 2013) - By therapy area
(Psychiatry)
- Figure 28: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Public
health)
- Figure 29: Online partnering resources
- Figure 30: Forthcoming partnering events
- Figure 31: Deal type definitions
- Figure 32: Pharmacogenomic partnering agreement between GlaxoSmithKline
and Response Genetics, May 2010
Pharmacogenomics Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited in April 10, 2013. This report consists of 416 Pages and the price starts from US $ 2795.
The contents of this page may be different from the latest version. Please contact us for details.
